Doctors Concerned By Massive Uptick In Teens Taking Ozempic
Teens are being prescribed Ozempic and similar drugs more than ever before — and some doctors are worried about what the trend could mean. In interviews with Reuters and Raleigh, North Carolina’s WRAL, doctors expressed disquiet at recent studies that found that are kids being prescribed the uber-popular jabs at increasing rates. Two recent studies, the […]
Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation
A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages.
Should AMA ‘Support’ a Registry to Track Side Effects of GLP-1 Drugs?
(MedPage Today) — CHICAGO — Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse events tied to blockbuster diabetes and weight-loss medications during an open forum at the AMA’s annual…
GLP-1 Medications Overtake Traditional Weight-Loss Drugs
The popularity of glucagon-like peptide-1 (GLP-1) receptor agonists continues, with use of tirzepatide and semaglutide surpassing that of traditional weight-lowering medications.
Amplifye debuts enzyme to supercharge protein digestion and unlock new health benefits
Amplifye, a UC Davis spinout led by former Amyris CEO John Melo, has launched its first product: a proprietary enzyme (P24) claimed to optimize protein digestion, unlocking a range of health benefits from improved blood glucose control to better sleep. Formerly known as Digestiva, Amplifye leverages computational protein design methods to discover novel enzymes, focusing […]
Specialty drug utilization grows
In 2024, the cost and utilization of specialty dermatology drugs significantly drove a 7% increase in pharmaceutical costs, according to a June 10 report from Navitus Health Solutions, a pharmacy benefits manager. Although specialty medications accounted for less than 2% of utilization, they drove 52% of net pharmaceutical spend in 2024, the report found. Per […]
Metsera’s drug shows potential in early clinical trial – statnews.com
Metsera’s drug shows potential in early clinical trial statnews.com Weight-loss newbie Metsera says once-monthly amylin matches GLP-1 efficacy FirstWord Pharma Obesity Startup Metsera Shares Rise on Early-Stage Trial Results Bloomberg.com Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks BioSpace Obesity Newcomer Metsera Enters The Ring With A Punch — And A […]
McDonald’s Shares Slump as GLP-1 Risks Spur Rare Sell Rating
McDonald’s Corp. shares slumped on Tuesday after Redburn Atlantic slapped the burger chain with its sole sell rating, saying shifting consumer patterns due to weight-loss drugs and inflation are cause for concern.
PSG Releases 2025 Drug Benefit Design Report: PBM Unbundling Gains Momentum and Payers Navigate GLP-1 Coverage Decisions Amid Rising Costs
DALLAS–(BUSINESS WIRE)–Pharmaceutical Strategies Group (“PSG”), an EPIC company, published its 2025 Trends in Drug Benefit Design Report, delivering critical insights into how payers are navigating a rapidly evolving pharmacy benefits landscape. For three decades, this industry report has been an essential resource for employers, health plans, and other stakeholders seeking to understand and adapt to […]
Lembas GLP-1 Ingredient Manufacturer Enters The Market Following $3.6 Million Pre-Seed Investment
Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss